
    
      Patients who have completed the Part2 of JR-171-101 study and fulfill all eligibility
      criteria can be enrolled in this JR-171-102 study. Until the dose determination in the
      JR-171-102 study, subjects will intravenously receive either low dose or high dose of JR-171
      at the same doses received at Week 12 of the JR-171-101 study. Thereafter, all subjects will
      be transitioned to the optimal dose determined based on the results of JR-171-101 study.
    
  